Fresh off its first drug approval, Alnylam announced positive interim data from a trial of another gene-silencing treatment on Thursday and said it hopes to file with the Food and Drug Administration for accelerated approval of the drug, givosiran, likely by the end of the year.

The Cambridge, Mass.-based company did not release any data Thursday, but said in a statement that an interim analysis of a Phase 3 trial of givosiran showed it successfully lowered levels of a chemical that regulators have said they will consider a surrogate endpoint to gauge the drug’s effectiveness.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy